Stocks / NASDAQ / Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

Our Opinion

Halozyme Therapeutics, Inc. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following article that they conduct pre-clinical trials of their drugs on animals.

“We are encouraged that these findings from our animal models continue to support the potential benefits of remodeling the tumor microenvironment in stimulating an immune response and improving the efficacy of checkpoint inhibitors and cell-based immunotherapies,” said Dr. Helen Torley, president and CEO.” Read the following article

Company Description

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA. [Source: MarketWatch]

Company Website: